SBP-101, a polyamine metabolic inhibitor, administered in combination with gemcitabine and nab-paclitaxel, shows signals of efficacy as first-line treatment for subjects with metastatic pancreatic ductal adenocarcinoma.

Nimit Singhal,Darren Sigal,Niall C. Tebbutt,Aram F. Hezel,Adnan Nagrial,Sumit Lumba,Thomas J. George,S Smith,Suzanne Gagnon,Michael G. Walker,Michael Cullen

SBP-101, a polyamine metabolic inhibitor, administered in combination with gemcitabine and nab-paclitaxel, shows signals of efficacy as first-line treatment for subjects with metastatic pancreatic ductal adenocarcinoma.

2021

Nimit Singhal
Darren Sigal
Niall C. Tebbutt
Aram F. Hezel
Adnan Nagrial
Sumit Lumba
Thomas J. George
S Smith
Suzanne Gagnon
Michael G. Walker
Michael Cullen

4127Background: SBP-101, a polyamine metabolic inhibitor, inhibited growth in 6 human pancreatic ductal adenocarcinoma (PDA) cell lines and 3 murine xenograft tumor models of human PDA. SBP-101 mon...

Keywords:

Gemcitabine
Polyamine
Medicine
tumor xenograft
Nab-paclitaxel
Cancer research
Cell culture
first line treatment
pancreatic ductal adenocarcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations